Pfizer

Quote












anonymous said:
Some of this information is incorrect. The Eliquis patent is not close to expiring. Field promotion of Eliquis has several more years. This is not a replacement for Eliquis. Eliquis field reps are not doing half their calls virtually. The expectation is around 15% but right now that percentage is not being reached. Pfizer also has a much smaller field force for womens health products. The Cardiology and Womens Health field forces are a combined total of about 750 reps nationally. All reps have single accountability territories.

The Tampa and Chicago call centers are calling on low value targets and targets who reside in areas where there is no field force presence. The jury is out on how effective this will be. Pfizer has made a huge investment in remote selling.

Pfizer had previously entered into a licensing agreement with Biohaven to promote Nurtec ODT in many markets outside of the USA. Pfizer has always been flush with cash but now even more so. This deal is all about adding product to fill pipeline gaps. At this point who knows how many Biohaven representatives are affected but I wouldn’t necessarily say it will be everyone.
Click to expand...
Accurate, with one exception- Pfizer call centers are calling on more than low -value targets. Virtual calls are low, but Pfizer field representatives are creative and have found a way to achieve the corporate goal. Pfizer management is committed to a virtual sales force.
If severance does occur upon acquisition, expect it within a year.
 






anonymous said:
The only reason we were purchased by Pfizer is that the co-ptomote of Eliquis is almost over due to expired patent life. Theres a slow down on revenue of the covid-19 vaccine. They have a small Eliquis sales force that will sell our migraine med. They don't want the reps from here , just the product to replace Eliquis. We are all toast. Get your resume updated and start looking for a new job.
All other Pfizer products are sold from the call centers in Chicago and Tampa.
Even if you are a field rep selling Eliquis you have to currently do half your calls virtually anyway, even if the office allows live visits. Pfizer is going to an eventual all remote model. There is no security even if you work for Pfizer as a live field rep.
Click to expand...

All true… Eliquis has ~ 18 months left. Most Pfizer folks won’t be happy about the merger, they were hoping for a buyout.
 






























anonymous said:
Thoughts? Do you think we will ok?
Click to expand...

In short....it depends. I saw a lot of people in my LinkedIn network getting hired in the recent hiring blitz getting district manager jobs. Nice people but the ones I knew were longtime primary care/contract folks. Nothing wrong with that but Pfizer has a certain "type" and these guys are not it. But as someone mentioned, these things take time (18-24 months) so stay alert, read the signs, and relax.
 






anonymous said:
In short....it depends. I saw a lot of people in my LinkedIn network getting hired in the recent hiring blitz getting district manager jobs. Nice people but the ones I knew were longtime primary care/contract folks. Nothing wrong with that but Pfizer has a certain "type" and these guys are not it. But as someone mentioned, these things take time (18-24 months) so stay alert, read the signs, and relax.
Click to expand...
? What "type" is that? How are they different than Nick L or Dave T?
 


















Well..you are an uninformed idiot. Pfizer has NO plans for layoffs..in fact they are doubling the sales force for this drug. Layoffs will surely come a couple years down the road but they need this drug to grow quickly and getting rid of the only people selling it is not in the plans.
 


















anonymous said:
Pfizer did not say they will be taking on Biohaven’s sales force. In fact, Pfizer said on the call they will not be adding any additional costs. They have the structure in place now. Pfizer’s current Internal Medicine sales force doubles Biohaven’s current sales force.
Click to expand...

Wrong..previous poster is correct.
 






anonymous said:
Some of this information is incorrect. The Eliquis patent is not close to expiring. Field promotion of Eliquis has several more years. This is not a replacement for Eliquis. Eliquis field reps are not doing half their calls virtually. The expectation is around 15% but right now that percentage is not being reached. Pfizer also has a much smaller field force for womens health products. The Cardiology and Womens Health field forces are a combined total of about 750 reps nationally. All reps have single accountability territories.

The Tampa and Chicago call centers are calling on low value targets and targets who reside in areas where there is no field force presence. The jury is out on how effective this will be. Pfizer has made a huge investment in remote selling.

Pfizer had previously entered into a licensing agreement with Biohaven to promote Nurtec ODT in many markets outside of the USA. Pfizer has always been flush with cash but now even more so. This deal is all about adding product to fill pipeline gaps. At this point who knows how many Biohaven representatives are affected but I wouldn’t necessarily say it will be everyone.
Click to expand...
 
























Top Bottom
Back
Quote